Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Anthonie W.A. Lensing"'
2
Akademický článek
Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Autor: Martin H. Prins, Anthonie W.A. Lensing, Paolo Prandoni, Philip S. Wells, Peter Verhamme, Jan Beyer-Westendorf, Rupert Bauersachs, Henri Bounameaux, Timothy A. Brighton, Alexander T. Cohen, Bruce L. Davidson, Hervé Decousus, Ajay K. Kakkar, Bonno van Bellen, Akos F. Pap, Martin Homering, Miriam Tamm, Jeffrey I. Weitz
Publikováno v: Blood Advances, Vol 2, Iss 7, Pp 788-796 (2018)
Abstract: The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In this prespecified analysis, we used data from 2 randomized trials, which compared once-daily rivaroxaban (20 mg or 10 mg) with aspirin (100 mg) or pla
Externí odkaz: https://doaj.org/article/6e056cdc7a37471ba8ae950a01ffc81e
Zobrazit plný text záznamu
4
Prevalence of pulmonary embolism among patients with recent onset of dyspnea on exertion. A cross-sectional study
Autor: Paolo Prandoni, Anthonie W.A. Lensing, Martin H. Prins, Maurizio Ciammaichella, Silvana Pirillo, Federica Pace, Beniamino Zalunardo, Fabrizio Bottino, Walter Ageno, Maria L. Muiesan, Marco Forlin, Luca Depietri, Carlo Bova, Nicoletta Costantini, Cosimo Caviglioli, Ludovica Migliaccio, Franco Noventa, Marcel Levi, Bruce L. Davidson, Gualtiero Palareti
Publikováno v: Journal of Thrombosis and Haemostasis, 21(1), 68-75. Wiley
Journal of thrombosis and haemostasis : JTH, 21(1), 68-75. Wiley-Blackwell
Background: Exertional dyspnea is a frequently encountered complaint in clinical practice. However, the prevalence of pulmonary embolism (PE) among patients with dyspnea on exertion has not been reported. Objective: The objective of this study was to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f87d78d5fbafa418b1237f3e4d70ac
http://www.scopus.com/inward/record.url?scp=85147048287&partnerID=8YFLogxK
Zobrazit plný text záznamu
5
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
Autor: Ingrid M. Bistervels, Roisin Bavalia, Martin Gebel, Anthonie W.A. Lensing, Saskia Middeldorp, Martin H. Prins, Michiel Coppens
Publikováno v: Journal of Thrombosis and Haemostasis, 20(6), 1376-1384. Wiley
Journal of Thrombosis and Haemostasis, 20, 6, pp. 1376-1384
Journal of thrombosis and haemostasis, 20(6), 1376-1384. Wiley-Blackwell
Journal of Thrombosis and Haemostasis, 20, 1376-1384
Contains fulltext : 251904.pdf (Publisher’s version ) (Open Access) BACKGROUND: Polypharmacy, including use of inhibitors of CYP3A4 and P-glycoprotein (P-gp), is common in patients with venous thromboembolism (VTE) and is associated with increased
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f79365fbfc1a077cebae0237e3b9e475
https://cris.maastrichtuniversity.nl/en/publications/1e7914fb-f824-4a4b-b2e2-8d4f04294e74
Zobrazit plný text záznamu
6
Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous Thrombosis
Autor: Mayte Sánchez van Kammen, Christoph Male, Philip Connor, Paul Monagle, Jonathan M. Coutinho, Anthonie W.A. Lensing
Publikováno v: Pediatric neurology, 128, 20-24. Elsevier Inc.
Background: We aimed to describe the clinical presentation, risk of bleeding and recurrent thrombosis, and perioperative anticoagulant management of children with cerebral venous thrombosis (CVT) and an associated head or neck infection. Methods: In
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a8805dd49f989679569b592610dfd4a
https://pubmed.ncbi.nlm.nih.gov/35032886
Zobrazit plný text záznamu
7
A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes
Autor: Alec Vahanian, Inge W.G. Bobbink, Maarten L. Simoons, Witold Rużyłło, Jean Boland, Uwe Zeymer, Victor A. Umans, Pentua Investigators, Frans Van de Werf, Anthonie W.A. Lensing, Martin Gardien, Peter Klootwijk
Publikováno v: Journal of the American College of Cardiology, 43(12), 2183-2190. Elsevier Inc.
Objectives In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS). Background Fondaparinux is a synthetic pentasaccharide that selectively inhibits activated clotting factor X. It
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6882b4b4a657fb108701548664ed0594
https://doi.org/10.1016/j.jacc.2004.02.051
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje